Loading
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Previous close
$4.86
+$0.16 · +3.40%
Regular session · ET · Market data may be delayed.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Day range
Current $4.86
52-week range
Current $4.86
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
53
Fair Value
Sentiment
64
Bullish
Risk
58
Elevated Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Day range
Current $4.86
52-week range
Current $4.86
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 42.73M USD | 108.3M USD | 113.31M USD | 3.65M USD | 40.96M USD |
| Cost of goods sold | 8.85M USD | — | — | — | — |
| Gross profit | 33.88M USD | 108.3M USD | 113.31M USD | 3.65M USD | 40.96M USD |
| Research and development | 182.78M USD | 159.68M USD | 130.01M USD | 115.86M USD | 121.88M USD |
| Selling, general, and administrative | 75.33M USD | 59.02M USD | 51.29M USD | 50.51M USD | 46.11M USD |
| Operating expenses | 249.26M USD | 218.71M USD | 181.3M USD | 166.37M USD | 167.98M USD |
| Interest income | 10.48M USD | — | — | — | 30K USD |
| Depreciation and amortization | 8.85M USD | 8.66M USD | 9.21M USD | 10.11M USD | 9.84M USD |
| Operating income | −215.38M USD | −110.4M USD | −68M USD | −162.72M USD | −127.02M USD |
| Net income | −204.38M USD | −97.01M USD | −57.51M USD | −161.82M USD | −122.25M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM16.65M0.02%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF9.67M0.01%93.7B USD0.05%$242.66+0.14%
State Street SPDR S&P Pharmaceuticals ETFXPH7.76M1.25%620.88M USD0.35%$70.93-0.14%
iShares Russell 2000 Value ETFIWN5.63M0.04%14.61B USD0.24%$224.62+0.40%
iShares Biotechnology ETFIBB5.58M0.05%10.73B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO4.26M0.02%17.4B USD0.06%$119.62+0.25%
Schwab U.S. Small-Cap ETFSCHA3.49M0.02%22.56B USD0.03%$34.55+1.01%
iShares U.S. Pharmaceuticals ETFIHE2.63M0.16%1.67B USD0.37%$104.68-0.70%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
